Cellectar Biosciences announced that is has received Notice of Allowance for the patent titled, “Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy,” from the Japanese, Chinese, Eurasian, Brazilian, and Mexican patent authorities. These patent allowances in key global regions follow prior allowances for the same patent in the US, Europe, Australia and Canada. The patent provides composition of matter and use protection for the Cellectar’s Phospholipid Drug Conjugate, PDC, platform as a targeted delivery vehicle in combination with a class of small molecules known as flavaglines. “The expansion of our global IP portfolio supports our plan to develop a diverse product portfolio delivering value across a broad range of therapeutic modalities beyond radiotherapies. In the immediate term, we look forward to reporting topline Waldenstrom’s macroglobulinemia pivotal data for our lead radioconjugate therapy, iopofosine I 131, in January 2024,” said James Caruso, president and CEO of Cellectar. “We are also focused on developing and expanding our pipeline of PDCs in additional high need cancers. Our robust global IP portfolio provides the foundation as we drive forward our mission to transform cancer care for people worldwide.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLRB:
- Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
- Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
- Cellectar Biosciences expects cash to fund operations into 2Q24
- Cellectar Biosciences announced a partnership with FCS
- Cellectar Biosciences appoints Yoon, Nanduri as VPs